🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: FF, 250 mcg

Found 14 matching trials

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

PHASE2

This is a randomized, placebo-controlled, 2-period crossover, escalating re...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-02-09

Trial ID

NCT02991859

Treatments Being Tested

Fluticasone furoate (FF) Dry Powder Inhaler Fluticasone propionate (FP) Dry Powder Inhaler Budesonide (BUD) Turbuhaler Placebo (ELLIPTA or DISKUS)

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

PHASE2

The purpose of the study is to determine the appropriate dose of fluticason...

Status

Completed

Location

Research Site

Start Date

2006-11

Trial ID

NCT00403286

Treatments Being Tested

Fluticasone Propionate/Formoterol Fumarate Fluticasone Propionate/Formoterol Fumarate Fluticasone Propionate/Formoterol Fumarate Fluticasone Propionate/Formoterol Fumarate Fluticasone Propionate Formoterol Fumarate Fluticasone Propionate/Salmeterol Xinafoate Placebo

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1

This study will evaluate the pharmacokinetics of FF, UMEC and VI administer...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-07-15

Trial ID

NCT01894386

Treatments Being Tested

FF 400 mcg UMEC 500 mcg UMEC 250 mcg VI 100 mcg

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

PHASE1

The purpose of this study is to demonstrate dose proportionality of the FF ...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-08-15

Trial ID

NCT01669070

Treatments Being Tested

FF, 50 mcg FF, 100 mcg FF, 200 mcg FF, 250 mcg

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-18

Trial ID

NCT01323621

Treatments Being Tested

Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg Fluticasone Propionate 250mcg / salmeterol 50mcg Double-dummy placebo Salbutamol as needed

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This will be a Phase IIIb multicentre, randomized, double-blind, double-dum...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-10-15

Trial ID

NCT01706328

Treatments Being Tested

FF/VI 100/25 Inhalation Powder NDPI Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS Placebo Inhalation Powder NDPI Placebo Inhalation Powder ACCUHALER/DISKUS Salbutamol as needed

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

PHASE3

Asthma is a common, chronic respiratory disease affecting 1-18 percent of t...

Status

Withdrawn

Location

Multiple Locations

Start Date

2019-01-18

Trial ID

NCT03376932

Treatments Being Tested

FF/UMEC/VI FP/SAL Tiotropium Albuterol/salbutamol ELLIPTA DPI DISKUS DPI RESPIMAT inhaler Metered Dose Inhaler Connected Inhaler System

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

PHASE3

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-18

Trial ID

NCT01323634

Treatments Being Tested

Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg Fluticasone Propionate 250mcg/ salmeterol 50mcg

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

PHASE2

The purpose of this study is to evaluate the dose-response of 4 doses of um...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-07-01

Trial ID

NCT02164539

Treatments Being Tested

FF UMEC VI

Previous Next